Abstracts

Impact of Archived Minority Populations With M184V/I on DTG/3TC for Maintenance of Viral Suppression

Background: There is limited evidence on the utility of proviral DNA sequencing to guide treatment changes in virologically suppressed persons with HIV (PWH) and prior virologic failures. VOLVER clinical trial aimed to evaluate if proviral DNA could assist in switching to dolutegravir/lamivudine (DTG/3TC) in PWH with history of 3TC resistance. Methods: Open-label single-arm multicentric clinical…

New HIV-1 Cell-Cell Transmission Assay Identifies Cell Type Dependency of PG9 And P16 Neutralization

Background: HIV-1 efficiently replicates in vivo by direct transmission from infected to uninfected CD4+ T cells, which is highly resistant to broadly neutralizing antibodies (bnAbs). But an accurate and sensitive measurement of HIV-1 transmission between cells remains challenging Methods: We developed an ultrasensitive HIV-1 cell-to-cell transmission assay that is based on a new vector, which…

Development of Individualized Antibody Treatment Regimens for Patients With Multidrug-Resistant HIV

Background: People living with HIV (PLWH) who harbor multidrug-resistant (MDR) viruses have limited therapeutic options and present extensive challenges in clinical management. We examined the capacity of HIV-specific broadly neutralizing antibodies (bNAbs) and anti-CD4 antibodies to suppress infectious viral isolates derived from PLWH with MDR viruses. Methods: We conducted immunologic and virologic analyses on 11…

Phenotypic Characterization of Replication-Impaired Lenacapavir-Resistant HIV Clinical Isolates

Background: Lenacapavir (LEN) is a potent, first-in-class long-acting HIV capsid (CA) inhibitor, approved by the FDA as a twice-yearly treatment option for people living with multi-drug resistant HIV. Out of 258 people with HIV (PWH) who received LEN in clinical studies, CA mutations were observed in 14 participants (M66I, Q67H/K/N, K70H/N/R/S, N74D/H, A105T/S, and T107A/C/N/S).…

Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1

Background: Monoclonal antibodies (mAbs) demonstrate diminished neutralisation of Omicron sub-lineages such that continued use of sotrovimab (SOT) is not supported by current pharmacokinetic-pharmacodynamic (PK-PD) understanding. However, SOT is still used in immunocompromised patients in some geographies. Published preclinical studies have shown virological efficacy in prophylaxis for BQ.1.1 but no data are available in treatment. This…

Viral and Symptom Rebound After COVID-19 Monoclonal Antibody Therapy in the ACTIV-2 Trial

Background: Risk of viral and symptom rebound after monoclonal antibody (mAb) therapy for COVID-19 is unknown. Methods: Viral and symptom rebound in a randomized placebo-controlled trial of combination mAbs Amubarvimab/Romlusevimab (A/R), which had been shown to reduce hospitalization/death by 79%, were explored. Symptom relapse was defined as first occurrence of any moderate/severe symptom (13 symptoms…

Large Fraction of COVID-19 Hospitalizations Preventable With Oral SARS-CoV-2 Antiviral Treatment

Background: Oral SARS-CoV-2 antiviral agents are an important treatment option for preventing severe COVID-19. We aimed to quantify the reduction in hospitalizations achievable through complete compliance with oral antiviral treatment guidelines in high-risk adults. Methods: Using electronic health record data from health systems in Minnesota and Nevada, we identified oral antiviral-eligible SARS-CoV-2 patients between April…

Nirmatrelvir/Ritonavir Reduces COVID-19 Symptom Duration Across Subgroups of Patients at High Risk

Background: Nirmatrelvir with ritonavir (nirmatrelvir/r) is an oral antiviral treatment for COVID-19. We report times to sustained alleviation and resolution of COVID-19 symptoms, overall and across subgroups of non-hospitalized adults with COVID-19 at increased risk of severe disease treated with nirmatrelvir/r compared to placebo (PBO). Methods: EPIC-High Risk (HR) was a Ph 2/3 double-blind, randomized,…

Shape-Shifting Tail Decay Is the Pharmacokinetic Profile of an Ultra-Long Acting Bictegravir Prodrug

Background: The advantages of long-acting (LA) antiretroviral therapy (ART) for regimen adherence and sustained viral suppression are unquestioned. However, the requirement for bi-monthly clinic visits, injection site reactions, large dosing volumes, and long pharmacokinetic (PK) tail pose notable challenges to widespread LA ART use. Consequently, there is an immediate need for ultra-LA (ULA) ART capable…

Preclinical Pharmacokinetics of a Novel Long-Acting Bictegravir Solid Injectable in Rats

Background: Bictegravir (BIC), is an integrase strand transfer inhibitor, effective for HIV treatment when combined with emtricitabine and tenofovir alafenamide. Another integrase inhibitor, cabotegravir, has been demonstrated to be effective in pre-exposure prophylaxis as a single agent and is available as a long-acting (LA) injectable medicine. This work describes preclinical pharmacology of a novel BIC…